Data Visualization of Treatment Patterns in Adults With BRAFV600E Mutant mNSCLC in Real-World Settings
Author(s)
David planchard, MD, PhD1, Sébastien Couraud, MD, PhD2, Céline Mascaux, MD, PhD3, Jean-Bernard Auliac, MD, PhD4, Daniel Christian Christoph, MD, PhD5, Lucia Bonomi, MD, PhD6, Antonio Chella, MD, PhD7, Enric Carcereny, MD, PhD8, Elvire Pons Tostivint, MD, PhD9, Diego Signorelli, MD, PhD10, Farida Beghdad, MSc11, Olivia Dialla, MSPH, DrPH, PharmD11, Sadya Khan, BSc, MSc11, Sanjay Popat, FRCP12.
1Gustave roussy, Villejuif, France, 2Lyon Sud Hospital, Lyon, France, 3University Hospital of Strasbourg - Nouvel Hôpital Civil, Strasbourg, France, 4Centre Hospitalier Intercommunal de Créteil, Créteil, France, 5Evang. Kliniken Essen-Mitte, Essen, Germany, 6Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII), Bergamo, Italy, 7Azienda Ospedaliero Universitaria Pisana, Pisa, Italy, 8ICO Badalona - Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 9CHU Nantes - Hôpital Guillaume et René Laënnec, Nantes, France, 10Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda-Milan, Milan, Italy, 11Pierre Fabre, Boulogne Billancourt, France, 12The Royal Marsden Hospital, London, United Kingdom.
1Gustave roussy, Villejuif, France, 2Lyon Sud Hospital, Lyon, France, 3University Hospital of Strasbourg - Nouvel Hôpital Civil, Strasbourg, France, 4Centre Hospitalier Intercommunal de Créteil, Créteil, France, 5Evang. Kliniken Essen-Mitte, Essen, Germany, 6Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII), Bergamo, Italy, 7Azienda Ospedaliero Universitaria Pisana, Pisa, Italy, 8ICO Badalona - Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 9CHU Nantes - Hôpital Guillaume et René Laënnec, Nantes, France, 10Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda-Milan, Milan, Italy, 11Pierre Fabre, Boulogne Billancourt, France, 12The Royal Marsden Hospital, London, United Kingdom.
OBJECTIVES: BRAF mutations occur in about 1-8% of NSCLC patients (pts), mostly in lung adenocarcinoma. The most prevalent variant is BRAFV600E. Due to the low number of cases, clinical features and treatment strategies for BRAFV600E mutant (BRAFMT) NSCLC are not well defined
METHODS: OCTOPUS is a multicentre, observational, descriptive, ambispective European study in adults with BRAFMT mNSCLC from Germany, France, Italy, Spain, and UK, who initiated either 1st systemic treatment in the metastatic setting from 01 Dec 2017 and prior to study entry (approximately 200 pts retrospectively and prospectively). This analysis describes pts and disease characteristics, BRAFMT testing practices, treatments pattern and effectiveness, progression free survival (PFS) for 1st line of treatment (1st LoT).
RESULTS: The study included 149 pts (135 retrospectives and 14 prospectives) median age 69 years (range 44.0-90.0) at diagnosis of metastatic disease, 54% male. Over half of pts (51.1%) were previous smokers, 22.2% current smokers, and 26.7% never-smokers. Majority of primary tumour histology was adenocarcinoma (93.3%) and 75.7% of pts had an ECOG of 0/1 at 1st LoT initiation. 87.8% of pts were TNM stage IV at diagnosis, 68.1% and 57.2% had non-visceral and visceral metastases, respectively, 17.2% had brain metastases. Of 135 pts tested for PD-L1, 41.5% had ≥50% tumor proportion score, 43.0% had 1%-49%, and 14.8% had <1%. NGS was the main BRAF testing method (62.5%) the median time from BRAFV600E testing to starting 1st LoT was 1 month. Targeted therapy only was the most frequent treatment at 1st LoT (47.7%). The median overall PFS in 1st LoT was 8.1 months.
CONCLUSIONS: These findings confirm that BRAFMT is more frequent in adenocarcinomas and is more likely to occur in pts with smoking history. BRAF testing turnaround time is long. These findings highlight the need to improve testing practices to increase the initiation of targeted therapy in 1st LoT.
METHODS: OCTOPUS is a multicentre, observational, descriptive, ambispective European study in adults with BRAFMT mNSCLC from Germany, France, Italy, Spain, and UK, who initiated either 1st systemic treatment in the metastatic setting from 01 Dec 2017 and prior to study entry (approximately 200 pts retrospectively and prospectively). This analysis describes pts and disease characteristics, BRAFMT testing practices, treatments pattern and effectiveness, progression free survival (PFS) for 1st line of treatment (1st LoT).
RESULTS: The study included 149 pts (135 retrospectives and 14 prospectives) median age 69 years (range 44.0-90.0) at diagnosis of metastatic disease, 54% male. Over half of pts (51.1%) were previous smokers, 22.2% current smokers, and 26.7% never-smokers. Majority of primary tumour histology was adenocarcinoma (93.3%) and 75.7% of pts had an ECOG of 0/1 at 1st LoT initiation. 87.8% of pts were TNM stage IV at diagnosis, 68.1% and 57.2% had non-visceral and visceral metastases, respectively, 17.2% had brain metastases. Of 135 pts tested for PD-L1, 41.5% had ≥50% tumor proportion score, 43.0% had 1%-49%, and 14.8% had <1%. NGS was the main BRAF testing method (62.5%) the median time from BRAFV600E testing to starting 1st LoT was 1 month. Targeted therapy only was the most frequent treatment at 1st LoT (47.7%). The median overall PFS in 1st LoT was 8.1 months.
CONCLUSIONS: These findings confirm that BRAFMT is more frequent in adenocarcinomas and is more likely to occur in pts with smoking history. BRAF testing turnaround time is long. These findings highlight the need to improve testing practices to increase the initiation of targeted therapy in 1st LoT.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
CO68
Topic
Clinical Outcomes, Methodological & Statistical Research
Topic Subcategory
Clinician Reported Outcomes
Disease
Oncology